Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Growth in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 400 shares, a growth of 187.8% from the August 31st total of 139 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ? days.

Basilea Pharmaceutica Stock Performance

Shares of BPMUF stock remained flat at $77.40 during midday trading on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11. The firm has a 50 day moving average of $71.07 and a 200 day moving average of $67.95. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $77.40.

About Basilea Pharmaceutica

Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland.

Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections.